NEWS ALERT SIGNUP STAY IN TOUCH HOME OUR COMPANY PRODUCT PORTFOLIO INVESTORS PRESS RELEASES CAREERS CONTACT Adding value is at the core of what we do For patients. For healthcare professionals. For payors. Who we are We are a specialty biopharma company committed to bringing innovative, value-added medicines that address the needs of underserved patient populations. We apply our knowhow and technological innovations to existing pharmaceuticals to unlock their hidden potential and address unmet medical needs. We have built a broad proprietary pipeline of complex value-added products with potential to offer significant advantages over currently available alternatives. Today, we have two, partnered commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, and Maxigesic® IV, a novel, dual mode-of-action non-opioid analgesic for the treatment of post-operative pain. Our development strategy of reformulating and repurposing approved pharmaceuticals primarily utilises the 505(b)(2) regulatory pathway in the U.S. and similar pathways in other countries, which are specifically designed for pharmaceutical agents for which the safety and efficacy have already been established. This focused strategy can dramatically reduce the clinical burden required to bring a product to market, and significantly shortens the development timelines while also reducing costs and risks. We focus on Value-Added Medicines, Pharma’s Sweet Spot Executive Management Stijn Van Rompay CHIEF EXECUTIVE OFFICER & CO-FOUNDER VIEW PROFILE Thomas Jacobsen CHIEF BUSINESS DEVELOPMENT OFFICER & CO-FOUNDER VIEW PROFILE Jean-Luc Vandebroek CHIEF FINANCIAL OFFICER VIEW PROFILE Dietmar Aichhorn CHIEF OPERATING OFFICER VIEW PROFILE Koenraad Van der Elst CHIEF LEGAL OFFICER VIEW PROFILE Hyloris Pharmaceuticals SA HQ: Boulevard Gustave Kleyer 17, 4000 Liège, Belgium T:+32 (0)4 346 02 07 E:contact@hyloris.com Quick links HOME INVESTORS OUR STRATEGY PRODUCT PORTFOLIO OUR COMPANY PRESS RELEASES CAREERS CONTACT News alert signup Stay updated on the latest developments at Hyloris. NEWS VIA EMAIL 2021 - Hyloris Pharmaceuticals SA - Design & Development by CLICK GDPR - Privacy Policy GDPR - Cookies Policy Terms of website use We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent. Cookie Settings Accept All